BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21343374)

  • 1. Placental growth factor upregulation is a host response to antiangiogenic therapy.
    Bagley RG; Ren Y; Weber W; Yao M; Kurtzberg L; Pinckney J; Bangari D; Nguyen C; Brondyk W; Kaplan J; Teicher BA
    Clin Cancer Res; 2011 Mar; 17(5):976-88. PubMed ID: 21343374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. sFLT01: a novel fusion protein with antiangiogenic activity.
    Bagley RG; Kurtzberg L; Weber W; Nguyen TH; Roth S; Krumbholz R; Yao M; Richards B; Zhang M; Pechan P; Schmid S; Scaria A; Kaplan J; Teicher BA
    Mol Cancer Ther; 2011 Mar; 10(3):404-15. PubMed ID: 21252283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion.
    Björndahl M; Cao R; Eriksson A; Cao Y
    Circ Res; 2004 Jun; 94(11):1443-50. PubMed ID: 15192038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human choriocarcinomas: placental growth factor-dependent preclinical tumor models.
    Bagley RG; Ren Y; Kurtzberg L; Weber W; Bangari D; Brondyk W; Teicher BA
    Int J Oncol; 2012 Feb; 40(2):479-86. PubMed ID: 22075622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis.
    Schomber T; Kopfstein L; Djonov V; Albrecht I; Baeriswyl V; Strittmatter K; Christofori G
    Cancer Res; 2007 Nov; 67(22):10840-8. PubMed ID: 18006829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer.
    Chiron M; Bagley RG; Pollard J; Mankoo PK; Henry C; Vincent L; Geslin C; Baltes N; Bergstrom DA
    Mol Cancer Ther; 2014 Jun; 13(6):1636-44. PubMed ID: 24688047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
    Krishnan B; Torti FM; Gallagher PE; Tallant EA
    Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating the role of angiogenesis in systemic lupus erythematosus.
    Liu J; Wang X; Yang X; Yan Q; Wang S; Han W
    Lupus; 2015 May; 24(6):621-7. PubMed ID: 25359881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VEGF-Grab Enhances the Efficacy of Radiation Therapy by Blocking VEGF-A and Treatment-Induced PlGF.
    Park I; Yang H; Park JS; Koh GY; Choi EK
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):609-618. PubMed ID: 30017791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma.
    Torimura T; Iwamoto H; Nakamura T; Abe M; Ikezono Y; Wada F; Sakaue T; Masuda H; Hashimoto O; Koga H; Ueno T; Yano H
    Neoplasia; 2016 Jul; 18(7):413-24. PubMed ID: 27435924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence.
    Taylor AP; Rodriguez M; Adams K; Goldenberg DM; Blumenthal RD
    Int J Cancer; 2003 Jun; 105(2):158-64. PubMed ID: 12673673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth.
    Yang X; Zhang Y; Yang Y; Lim S; Cao Z; Rak J; Cao Y
    Proc Natl Acad Sci U S A; 2013 Aug; 110(34):13932-7. PubMed ID: 23918367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placenta growth factor is a survival factor for human malignant mesothelioma cells.
    Albonici L; Doldo E; Palumbo C; Orlandi A; Bei R; Pompeo E; Mineo TC; Modesti A; Manzari V
    Int J Immunopathol Pharmacol; 2009; 22(2):389-401. PubMed ID: 19505392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs.
    Hedlund EM; Yang X; Zhang Y; Yang Y; Shibuya M; Zhong W; Sun B; Liu Y; Hosaka K; Cao Y
    Proc Natl Acad Sci U S A; 2013 Jan; 110(2):654-9. PubMed ID: 23267058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
    Bdolah Y; Lam C; Rajakumar A; Shivalingappa V; Mutter W; Sachs BP; Lim KH; Bdolah-Abram T; Epstein FH; Karumanchi SA
    Am J Obstet Gynecol; 2008 Apr; 198(4):428.e1-6. PubMed ID: 18191808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
    Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
    Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
    J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fusion protein with the receptor-binding domain of vascular endothelial growth factor-A (VEGF-A) is an antagonist of angiogenesis in cancer treatment: Simultaneous blocking of VEGF receptor-1 and 2.
    Tseng FJ; Chen YC; Lin YL; Tsai NM; Lee RP; Chung YS; Chen CH; Liu YK; Huang YS; Hwang CH; Lai YK; Liao KW
    Cancer Biol Ther; 2010 Nov; 10(9):865-73. PubMed ID: 20818186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Anti-PLGF and Anti-Endostatin Treatments Inhibit Ocular Hemangiomas.
    Jiang H; Wu X; Wang H; Huang C; Zhang L
    Cell Physiol Biochem; 2015; 36(3):930-6. PubMed ID: 26088746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.